Treatment of Nipah Virus Infection in Myocarditis
Clinical scenario
Nipah virus infection can present with myocarditis as one of its recognised syndromic complications. This protocol addresses the management of Nipah-associated myocarditis, where cardiac involvement drives the clinical course.
Presenting condition
Myocarditis is a direct syndromic presentation of Nipah virus infection. When present, it produces acute heart failure physiology requiring targeted haemodynamic management distinct from uncomplicated Nipah infection.
Management approach (overview only)
Care centres on supportive therapy addressing the haemodynamic consequences of acute heart failure — including vasodilator and diuretic strategies — combined with inotropic support selected according to the patient's blood pressure status.
Full agent selection logic, titration ranges, and the complete regimen are available in the structured protocol below.
References
- The syndromic presentations are ARDS, Myocarditis and Encephalitis.
- Supportive therapy for symptoms of acute heart failure with use of diuretics, nitroprusside, ACE inhibitors.
- Inotropes — Dobutamine: Inotrope and potential vasodilator; lowers blood pressure; give as individual agent as long as systolic blood pressure (SBP) ≥90. Can use with dopamine.
- Dopamine: Inotrope and vasoconstrictor; increases left ventricular end-diastolic pressure and causes tachycardia. Can be used with dobutamine.
- Norepinephrine: Vasoconstrictor and inotrope; preferred as a single agent over dobutamine if SBP <70. Can use combined with dobutamine.
View source ↗